We are driving the development of therapies for rare and very rare diseases.
Evkeeza® (evinacumab)
Evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH).
Click here to view the picture of the medication bottle
Summary of Product Characteristic and Patient Information Leaflet
Summary of Product Characteristics and Patient Information Leaflet for this medicine are available on the European Medicines Agency website:
https://www.ema.europa.eu/en/documents/product-information/evkeeza-epar-product-information_de.pdf
Access
Evkeeza is currently undergoing a NICE Single Technology Appraisal. See,
https://www.nice.org.uk/guidance/indevelopment/gid-ta10655
Ordering information for pharmacies
To provide Tanner details
Reporting any potential adverse events, safety information,
or product complaints
Adverse Events
Adverse events should be reported. Reporting forms and information
can be found at (UK):https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to [email protected] or call 0203 1399039
Medical Information
For any questions about our medicines,
please contact: [email protected] or
call 0203 1399039
Product Complaints
For product complaints,
please contact: [email protected] or
call 0203 1399039
Mepsevii® (vestronidase alfa)
Mepsevii (vestronidase alfa) is indicated for the treatment of non-neurological manifestations of Mucopolysaccharidosis
VII (MPS VII; Sly syndrome).
Click here to view the picture of the medication bottle
Summary of Product Characteristics and Patient Information Leaflet
Mepsevii (vestronidase alfa) Summary of Product Characteristics and Patient Information Leaflet are available at:
https://www.ema.europa.eu/en/documents/product-information/mepsevii-epar-product-information_de.pdf
[MSCSmOC Link]
Access
Mepsevii is recommended to be available as a routine commissioning as a treatment option for infants with MPS VII within the criteria set out in this Clinical Commissioning Policy Statement:
https://www.england.nhs.uk/wp-content/uploads/2022/11/2202-policy-statement-vestronidase-alfa.pdf
Ordering information for pharmacies
To provide Tanner details
Reporting any potential adverse events, safety information,
or product complaints
Adverse Events
Adverse events should be reported. Reporting forms and information
can be found at (UK): https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to [email protected] or call 0203 1399039
Medical Information
For any questions about our medicines,
please contact: [email protected] or
call 0203 1399039
Product Complaints
For product complaints,
please contact: [email protected] or
call 0203 1399039
